← Back to Analyst Consensus 
CAMP Buy
Camp4 Therapeutics Corp
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 3 upgrades / ▼ 0 downgrades / 1 reiterations from 4 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 23, 2026 | Raymond James | initiate | — → Strong Buy | — | 54% |
| Oct 15, 2026 | Needham | initiate | — → Buy | — | 50% |
| Oct 5, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Sep 29, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Aug 14, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Jun 16, 2026 | JP Morgan | upgrade | Neutral → Overweight | — | 54% |
| Jun 10, 2026 | Chardan Capital | initiate | — → Buy | — | 47% |
| Apr 14, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Apr 2, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Oct 2, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $7 | 50% |
| Sep 16, 2025 | JP Morgan | downgrade | Overweight → Neutral | $0 | 54% |
| Sep 15, 2025 | Piper Sandler | maintain | Overweight → Overweight | $12 | 54% |
| May 27, 2025 | Wedbush | initiate | — → Outperform | $8 | 58% |
| Nov 5, 2024 | William Blair | initiate | — → Outperform | $0 | 48% |
| Nov 5, 2024 | Leerink Partners | initiate | — → Outperform | $17 | 51% |
| Nov 5, 2024 | JP Morgan | initiate | — → Overweight | $23 | 54% |
| Nov 5, 2024 | Piper Sandler | initiate | — → Overweight | $18 | 54% |
Price Target Trend
May 13, 2026 Latest: $10.22 Oct 24, 2026
EPS Estimates
+1y $-0.85
Lo: $-1.04 Hi: $-0.70
5 analysts ▲2
+1q $-0.22
Lo: $-0.31 Hi: $-0.16
5 analysts ▲2
0q $-0.22
Lo: $-0.28 Hi: $-0.15
5 analysts ▲1
0y $-1.13
Lo: $-1.39 Hi: $-0.71
4 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days